Cormorant Asset Management, LP - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 44 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.8%.

Quarter-by-quarter ownership
Cormorant Asset Management, LP ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2023$464,099,700
+11.8%
8,142,1000.0%27.07%
+16.4%
Q2 2023$415,247,100
+281572.4%
8,142,100
+18.1%
23.26%
+139.6%
Q1 2023$147,422
+131.5%
6,892,101
+13.6%
9.71%
+127.9%
Q4 2022$63,683
-99.9%
6,065,0010.0%4.26%
+29.5%
Q3 2022$47,064,000
+52.4%
6,065,0010.0%3.29%
+40.9%
Q2 2022$30,886,0006,065,0012.34%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q1 2023
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$1,239,823,18833.43%
Cormorant Asset Management, LP 8,142,100$464,099,70027.07%
Ally Bridge Group (NY) LLC 183,105$10,436,98512.25%
Finepoint Capital LP 331,416$18,890,7129.41%
Ghost Tree Capital, LLC 330,000$18,810,0006.19%
5AM Venture Management, LLC 313,210$17,852,9705.14%
Ghost Tree Capital, LLC 250,000$14,250,0004.69%
MPM BioImpact LLC 294,190$16,768,8304.48%
Integral Health Asset Management, LLC 500,000$28,500,0003.95%
Altium Capital Management LP 88,000$5,016,0002.62%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders